Reply to non final office action Appln. 10/528,073 VALKNA et al.

CLAIM LISTING

This claim listing replaces any and all previous claim listings.

1-18 (cancelled)

- 19. (Currently amended) A recombinant fusion protein consisting of comprising at least (a) scFv-part of an antibody, (b) a linker; and (bc) a cell penetrating transport peptide, wherein the protein is expressed from an expression vector cloned into a host cell.
- 20. (Currently amended) A recombinant fusion protein <u>consisting of comprising at least</u> (a) a scFv-part of an antibody recognising an intracellular GLI-protein, chosen from GLI-1 and GLI-3, (b) a linker; and (bc) a cell penetrating transport peptide, and wherein the protein is expressed from an expression vector cloned into a host cell.
- 21. (Currently amended) <u>The A-recombinant fusion protein according to claim 1920-</u>, wherein the cell-penetrating transport peptide <u>consists of comprises at least a part of Transportan</u>, Transportan 10 or Arg 9.
- 22. (Previously amended) The recombinant fusion protein according to any one of claims 19 or 21, wherein the scFV-part is obtained from the human genome.
- 23. (Currently amended) The recombinant fusion protein according to claim 19, wherein said protein is allowed to enter into a human cells *in vitro* and inactivate an intracellular target of the scFv-part. medical use.

24-25 (Cancelled)

26. (Cancelled)

Reply to non final office action Appln. 10/528,073 VALKNA et al.

- 27. (Withdrawn) Method for obtaining a fusion protein as defined in claim 19, wherein the method comprises the steps of expressing the fusion protein and purifying the obtained fusion protein.
- 28. (Withdrawn) Method for treatment of a disease or health disorder in humans or animals, comprising administrating a pharmaceutically acceptable dose of the fusion protein as defined in claim 19 to humans or animals.
- 29. (Withdrawn) The method according to claim 28, wherein the disease or health disorder is cancer.
- 30. (Withdrawn) The method according of claim 29, wherein the cancer is skin cancer.
- 31. (Currently amended) The recombinant fusion protein according to claim 19, wherein the cell penetrating transport peptide comprises at least a part of Transportan.
- 32. (Currently amended) The recombinant fusion protein according of claim 19, wherein the cell-penetrating transport peptide comprises at least a part of Transportan 10.
- 33. (Currently amended) The recombinant fusion protein according to claim 19, wherein the cell-penetrating transport peptide comprises at least a part of Arg 9.